David R. Gandara, MD
University of California Davis Comprehensive Cancer Center, Sacramento, CA., USA
David R. Gandara, MD is a Professor of Medicine at the University of California at Davis (UCD) School of Medicine, is the Senior Advisor to the Director, and Director of the Thoracic Oncology Program at UC Davis Comprehensive Cancer Center (UCDCCC). He is a diplomat of the American Board of Internal Medicine specializing in Medical Oncology. He has led a large number of research projects in lung cancer, including early therapeutics trials at various phases, cooperative group trial through the Southwest Oncology Group (SWOG), and translational science projects. He is the clinical director for a National Cancer Institute (NCI) award to the California Cancer Consortium for Early Therapeutic Trials of New Anti-Cancer Agents. He is past chair of the SWOG Lung Committee (1997-2015), and a member and founding co-chair of the NCI-directed Investigational Drug Steering Committee (IDSC). He has written over 700 articles, book chapters, abstracts and editorials. He is Editor-in-chief of the journal Clinical Lung Cancer. He served as president of the International Association for the Study of Lung Cancer (IASLC) from 2009 to 2011 and is on the IASLC board of directors, serving as treasurer since 2013. He is a prior board member and secretary-treasurer of the American Society for Clinical Oncology (ASCO). Most recently, he serves as Clinical Director for the joint Jackson Laboratory (JAX)-UCDCCC patient-derived xenotransplant (PDX) program in lung cancer, and is UCDCCC principal investigator for the SU2C dream team in KRAS-mutated lung cancer.